Can chemotherapy stop immunotherapy from backfiring in lung cancer?

This study is for people with advanced non-small cell lung cancer (NSCLC) who have a specific biomarker that puts them at high risk for a dangerous side effect called hyperprogression, where immunotherapy can cause tumors to grow much faster. Researchers want to see if starting treatment with a combination of immunotherapy (cemiplimab) and chemotherapy can prevent this rapid growth, compared to using immunotherapy alone. The goal is to find a safer, more effective first treatment for these patients.